Studies of HIV dynamics in AIDS research are very important for understanding pathogenesis of HIV infection and for assessing the potency of antiviral therapies. Since the viral dynamic results from clinical data were first published by Ho et al. and Wei et al., the study of HIV-1 dynamics in vivo has drawn a great attention from AIDS clinicians and researchers. Although the important findings from HIV dynamic studies have been published in many prestigious scientific journals, statistical methods for estimating viral dynamic parameters have not been paid enough attention by HIV dynamic investigators. The estimation methods in many viral dynamic studies are very crude and inefficient. In this paper, we review the statistical methods and mathematical models for HIV dynamic data analysis developed in recent years. We also address some practical issues and share our experiences in the design and analysis of viral dynamic studies. Some principles and guidelines for the design and analysis of viral dynamic studies are provided. The methodologies reviewed in this paper are also applicable to studies of other viruses such as hepatitis B virus or hepatitis C virus. We also pose some challenging statistical problems in this area in order to stimulate further study by the statistical research community.
Introduction
Recently, highly active antiretroviral therapies (HAART) have become available for HIV infected patients. The HAART treatments can rapidly reduce the amount of virus in the plasma of infected individuals to a very low level. The development of sensitive assays for quantifying plasma HIV-1 RNA concentrations allows us to monitor the elimination process of plasma virus during treatment. An HIV-1 dynamic study is one of the new developments in AIDS research, which results in a new understanding of the pathogenesis of HIV-1 infection. [1] [2] [3] [4] [5] [6] As characterization of viral dynamics in different patient populations with different treatment regimens can provide useful guidelines for development of treatment strategies and provide information for evaluation of treatment efficacy, [7] [8] [9] we can envisage that more studies on viral dynamics will be developed in the future. However, due to the complexity of viral dynamic models, it is challenging to develop statistical methods for designing viral dynamic studies and fitting the clinical data to the viral dynamic models. The importance of viral dynamic studies and development of statistical tools has been recognized by Anderson and Darby 10 and Donnelly. 11 Some of the statistical methods for viral dynamic studies have been mentioned and briefly reviewed recently by Donnelly and Cox 12 and Raab and Parpia. 13 In this paper, we give a comprehensive review of the new development of statistical methods for HIV dynamic data analysis and inference in the past several years to echo the strong impact of HIV dynamic studies in AIDS research. Our purposes are two fold. The first is to stimulate more statistical methodologists to join the battle against AIDS epidemic, in particular, to develop badly needed statistical methods for HIV dynamic studies. The statistical challenges will be posed throughout the paper. Another objective is to provide a systematic and comprehensive review on available statistical methods for medical statisticians and AIDS clinical researchers, who are interested in design and analysis of HIV dynamic studies. Author and coworkers have dedicated the past several years to the development of statistical methods for HIV dynamics, and we have analysed viral dynamic data from seven clinical trials which include both pediatric and adult AIDS studies. We also participated in the design of some of these viral dynamic studies. We shall share our practical experience through this paper.
We organize the rest of the paper as follows. In Section 2, we give a brief review of mathematical models for HIV dynamics in which we will emphasize the applicable models for clinical data analysis. We review the model-fitting methods that include the nonlinear least squares (NLS) method, the nonlinear mixed-effects model (NLME) approach, semi-parametric model fitting and the Bayesian approach in Section 3. Some other practical issues such as initial values for model fitting algorithms, data screening and effect of model assumptions will also be discussed. In Section 4, we focus on statistical inference based on NLME viral dynamic models that include treatment comparisons, covariate effects for viral dynamic parameters, correlations with other virological or immunological response surrogate endpoints. In Section 5, we discuss the design issues for HIV dynamic studies. We conclude the paper with a brief discussion of conclusion and future direction in Section 6.
Mathematical models
Modeling the interaction of HIV with cells of the immune system can be traced back to the late 1980s. [14] [15] [16] [17] [18] [19] [20] [21] [22] Most of these earlier mathematical models, including the models developed by biomathematicians and theoretical biologists in the early 1990s, [23] [24] [25] [26] [27] [28] [29] [30] were used for computer simulations and interpretation of CD4þ T cell decline after HIV infection. The simplified versions of these models have been applied to fit HIV RNA (viral load) data and have resulted in important findings on the mechanisms of HIV infection since the HIV RNA assays became available in the mid-1990s. [1] [2] [3] [4] [5] [6] In the first two seminal papers on in vivo HIV dynamics by Ho et al. 1 and Wei et al., 2 simple one-exponential and two-exponential models were used to fit the HIV-1 RNA data during the early stage of antiviral treatment, in which the first phase viral decay (the clearance rate of productively infected cells 3, 4 ) was estimated to have a half-life of about two days. Later, Perelson et al. 3 extended the viral dynamic model with an assumption of a perfect treatment effect for potent protease inhibitor (PI) drugs as follows:
where T represents the concentration of uninfected CD4þ T cells which are the targets of HIV, T* denotes the concentration of productively infected T cells, V I is the plasma concentration of infectious virions, V NI denotes the concentration of noninfectious virions, c is the clearance rate of virus, d is the clearance rate of productively infected cells, k is the infection rate and N is the number of new virions produced per infected cell during its life time. Note that the effect of PI drugs is to make the infectious virions become noninfectious. Under the assumption of constant T in a short period of treatment and quasi-steady state before drug treatment, a closed-form solution to the above system of linear differential equations can be obtained. The total concentration of plasma virions,
can be written as
Perelson et al. 3 fitted this model to more frequent HIV-1 RNA data (15 data points per subject) during the first week of treatment, and found that the half-life of free virions was about six hours and the half-life of productively infected cells was 1.6 days. Perelson et al. 4 further proposed a model for a longer period of treatment from which a biphasical decay of plasma HIV-1 RNA was observed. In this model, more compartments such as long-lived infected cells, M*, and latently infected lymphocytes, L, were considered in addition to the productively infected cells T*. It was assumed that cells such as macrophages (M) may be infected by HIV with an infection rate k M and become long-lived infected cells. The model can be written as
where more details on the notation and justification of this model can be found in Perelson et al. 4 Under the assumptions of perfect drug and pretreatment steady state as earlier, a closed-form solution for V(t) to the system (2) can be found to be,
where A, B and C are functions of system parameters (detailed in Perelson et al. 4 ), and V 0 is baseline viral load. This model is too complicated for all parameters to be identified from plasma HIV-1 RNA data. The data from peripheral blood mononuclear cells infectivity were also used and some of the parameters such as clearance rate of free virions (c) were assumed to be known from the previous study. 3 The plasma HIV-1 RNA data during six weeks of antiviral treatment were used to fit the model and the half-life of productively infected cells, long-lived infected cells and latently infected cells was estimated as 1.1 days, 14.1 days and 8.5 days, respectively. Huang, et al. 31 recently proposed a viral dynamic model with time varying treatment effects,
where g(t) represents a time varying treatment efficacy, which can be modeled as a function of drug exposure (pharmacokinetics and adherence) and drug sensitivity (measured by a phenotypic test such as IC 50 ). For example,
, where C min is the minimum concentration of drug in plasma. Although IC 50 can be measured by phenotype assays in vitro, it may not be equivalent to the IC 50 in vivo. Parameter F indicates a conversion factor between the two. The effect of adherence, A(t), can be modeled as a binary process, where A(t) ¼ 1 indicates that a dose is taken and A(t) ¼ 0 otherwise. Parameter l in Model (3) represents the rate at which new T cells are created from sources within the body, such as the thymus, and r is the death rate of T cell. Other notations are similar to previous models. Because 'all models are wrong and only some models are useful', we should develop useful models for different scientific purposes. Wu and Ding 33 suggested a modeling strategy to consider all possible compartments in the model first, and then simplify the model into a useful (applicable) model based on the available data. The following cell and virus compartments may be considered: 1) uninfected target cells, such as T cells, macrophages, lymphoid mononuclear cells and tissue langerhans cells, which are possible targets of HIV-1 infection; 2) 'mysterious' infected cells, cells other than T cells, such as tissue langerhans cells and microglial cells whose behavior is not completely known; 3) long-lived infected cells, such as macrophages, that are chronically infected and long-lived; 4) latently infected cells, which contain the provirus but are not producing virus immediately, and only start to produce virus when activated; 5) productively infected cells, which are actively producing virus; 6) infectious virus, virus that is functional and capable of infecting target cells and 7) noninfectious virus, virus that is dysfunctional and cannot infect target cells. To avoid identifiability problem, Wu and Ding 33 suggested regrouping the parameters into macroparameters to simplify the model. This can avoid the assumption of steady state before treatment, which may not be true for some cases. 3, 4 For example, if very frequent viral data are available for the first several days of antiviral treatment, the 'shoulder' effect 32 can be observed due to the mechanism of PI drug actions. The model proposed in Perelson et al. 3 may be used in this case. However, if the frequent data on the 'shoulder' effect are not available, Wu and Ding 33 suggest a simple two-exponential model,
where t c is the time when the 'shoulder' effect ends. This model ignores the 'shoulder' effect, as no data are available. The macroparameters d 1 and d 2 are the viral decay rates that can be estimated from clinical data, but the interpretation of d 1 and d 2 with imperfect drug treatment may be complicated. Ding and Wu 9 have shown that
where e 1 and e 2 are treatment effects, R 1 and R 2 are baseline viral production/clearance ratios and d 1 and d 2 are death rates of infected cells in the two compartments of productively infected cells and long-lived/latently infected cells, respectively. More biological interpretations of the observed decay rates (d 1 and d 2 ) are found in Wu et al.
All the models introduced earlier require an assumption of constant uninfected target cells to obtain a closed-form solution to the differential equations. This assumption is valid during the early stage of antiviral treatment before viral rebound occurs due to treatment failure. Thus, the viral rebound data need to be excluded, in order to fit the earlier models. The data exclusion may be different for different subjects and is quite arbitrary. To avoid this problem, Wu and Zhang 35 proposed a semi/parametric model:
The difference between this model and Model (4) is that the second phase decay rate in Model (5) is not constant, instead it is a nonparametric smooth function of treatment time t. This semiparametric model enjoys both interpretability of the original parametric Model (4) and flexibility of a nonparametric model. First, the biexponential form of the model is preserved. Thus, the biological compartmental theory 4, 9, 33 is approximately valid for interpretation, especially the estimated constant d 1 , which represents the turnover rate of productively infected cells. Actually because the long term viral load data are included, the estimate of d 1 is expected to be more accurate and reasonable than the existing models. This semiparametric model can accommodate long term viral dynamics. All viral load data (including rebound data) can be used to fit this model (see section 3 for model fitting).
Recently, more mathematical models for HIV dynamics have been proposed. [36] [37] [38] Some of these models are very complicated and may include the immune responses against HIV and other compartments. No closed-form solution is available for complicated dynamic models. This may pose a challenge when trying to identify the parameters in these models. We shall introduce the Bayesian framework to address this issue in Section 3.
3 Model ¢tting methods
Least squares methods
In an earlier work, standard NLS regression methods were used to fit viral dynamic models. [1] [2] [3] [4] The NLS method is a simple and popular method to estimate unknown parameters in a nonlinear system. In viral dynamic studies, we are able to obtain the data for the total virus load,
be the solution (either numerical or closed-form) of viral load for a differential equation model introduced in Section 2, with b being the unknown parameter, and y(t) the measurement of viral load at treatment time t. Then a nonlinear regression model can be written as
, where e(t) is a measurement error process with mean zero. The least squares (LS) estimate of b minimizes:
Standard inference methods in nonlinear regressions [39] [40] [41] can be applied here. Standard nonlinear regression procedures in S-plus, SAS and other statistical packages are available to fit the model to clinical data. Usually, a log transformation of the data is used to stabilize the variance of measurement error and the estimation algorithms. The parameters for each individual subject need to be estimated independently, which requires frequent data from each individual and may not be efficient. Thus, a more powerful mixed-effects model approach was proposed by Wu et al. 42 and Wu and Ding. 33 
Mixed-e¡ects model approach
Wu et al. 42 and Wu and Ding 33 first proposed using a NLME model approach to fit HIV viral dynamic data. The standard NLS method requires that the HIV-1 RNA data from each individual are frequent to fit a complicated nonlinear model, which may not be achievable from a relatively medium or large clinical study. In addition, some patients may miss the scheduled clinical visits for HIV-1 RNA measurements, and some patients may drop out of study early owing to toxicities and other reasons. In these cases, these patients have to be excluded from the analysis, as the viral load data may not be enough to fit the nonlinear viral dynamic model using the NLS method. This may result in biased inference and misleading conclusions. The NLME model approach suggested by Wu et al. 42 and Wu and Ding, 33 however, can pool individual data together to estimate the population parameters first, and then estimate the individual parameters by the empirical Bayesian method. 43, 44 The NLME model approach is flexible for dealing with individually sparse data. 42 This technique has been widely used in modeling pharmacokinetics/pharmacodynamics. 43, 44 The NLME or hierarchical nonlinear models 43, 44 can be briefly described as follows:
Within-subject variation, for the ith subject:
Stage 2. Between-subject variation:
where y i is an (n i Â 1) vector of the observed HIV-1 RNA data from the ith subject (usually the log-scale is used to stabilize the measurement variance and estimation algorithms), and e i are the corresponding within-subject measurement errors. The vector function f(
is a solution of viral load to viral dynamic differential equations introduced in the last section. V (Á, b i ) can also be a closed-form solution to a set of differential equations such as the model described by Equation (4). The parameter vector b i is a (p Â 1) vector of individual specific viral dynamic parameters and x i are the independent variables (usually time t in our case).
Here d (a i , b, b i ) is a p-dimensional function of the between-subject covariate vector a i , the population parameter vector b and between-subject random effects b i . This function may be linear or nonlinear. Although the individual NLS estimates can be pooled together to obtain the population estimates of parameters in the hierarchical model using so-called standard two-stage method or global two-stage method, 43, 44 linearization methods are more efficient. Beal and Sheiner 45 proposed a maximum likelihood method for the parameter estimation, while Vonesh and Carter 46 suggested the use of an iterative generalized least squares (GLS) method. Lindstrom and Bates 47 proposed their iterative GLS algorithm based on conditional first order linearization. The detailed reviews of these model fitting procedures can be found in Davidian and Giltinan 43 and Vonesh and Chinchilli. 44 Details on applications of NLME models to viral dynamic analysis can be found in Wu et al. 42 and Wu and Ding. 33 The S-plus NLME function 48 and the SAS PROC NLMIXED, as well as PK/PD software such as NONMEM, 49 can be used to fit the model. From the NLME modeling approach, we can obtain both population and individual estimates for viral dynamic parameters. The individual estimates are empirical Bayesian estimates and are the best linear unbiased predictors. From statistical software's output, we may also obtain the standard error for the population estimates. The estimates of between-subject variation D and within-subject variation R i are also available and may be reported. Some summary statistics such as mean, median and quartiles of individual estimates are also helpful in the analysis report. Some important inference issues in the NLME models will be addressed in Section 3.3.
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Semiparametric model ¢tting
Similarly, the semiparametric Model (5) can be written as a hierarchical mixed-effects model,
. . , n and j ¼ 1, 2, . . . , n i , and n and n i are the number of subject and the number of measurement from the ith subject. Note that the time varying second phase decay rate d i2 (t) can be decomposed into a population curve g(t) and random curves h i (t). To fit this semiparametric model, we may apply the regression spline method. The working principle is briefly described subsequently (for more details, refer Wu and Zhang 35 or Rice and Wu 50 ).
The main idea of the basis based regression spline approach is to approximate g(t) and h i (t) using linear combinations of basis functions. For instance, g(t) can be approximated by a linear combination of the basis functions c p
where p is the number of basis functions and l p ¼ (m 0 , . . . , m pÀ1 ) is the vector of coefficients. Similarly,
where Fq(t) ¼ {f 0 (t), . . . , f q 7 1 (t)} T are basis functions, and n iq ¼ (x i0 , . . . , x i(q 7 1) ) are the vector of coefficients. Then Model (8) can be approximated by
Thus, for given C p (t) and F q (t), we approximate a semiparametric nonlinear mixedeffects model by a standard parametric NLME model with time dependent covariates. By doing so, the randomness of the nonparametric mixed-effects is transferred to the randomness of the associated coefficients, whereas the nonparametric nature is represented by the basis functions. The NLME model, Model (11) , can be solved by using existing NLME algorithms such as that of Lindstrom and Bates 47 (readily available in S-plus, SAS and other statistical packages), resulting in the estimatorsl p ,n iq and other useful quantities. We therefore obtain the estimates of the nonparametric (time varying) parameters,
For convenient implementation, we may use natural cubic spline bases which are available in many statistical software packages such as S-plus. The smoothing parameters p and q can be selected using model selection criteria such as AIC or BIC. 43 The percentile based knot placing rule (locating the knots at the sample percentiles of the design time points) may be used to select the knots. 51, 52 For more details, refer to Wu and Zhang. 35 
Bayesian approach
Some of the proposed viral dynamic models are nonlinear differential equations, such as Model (3) in Section 2, to which no closed-form solution is available. There are also many unknown parameters in these models. For instance, seven unknown parameters in Model (3) include f, l, r, d, k, N and c. This poses the challenge of how to identify all these parameters in a nonlinear differential equation model for viral dynamics. In fact, it is impossible to identify all these parameters using only viral load data. Some prior information is necessary to help with the parameter identification. To efficiently use prior information to identify more parameters, we need to resort to Bayesian methods which have been recently studied to estimate viral dynamic parameters by Forst, 53 Han et al. 54 and Putter et al. 55 We illustrate the basic idea using the simplified viral dynamic model, Model (3).
Let subject specific parameters
We use the log transformation of the parameters to guarantee their positivity. We also denote Y ¼ {y 1 , y 2 , . . . , y n } and Y {i} ¼ {y l , l 6 ¼ i}. The Bayesian NLME can be written in the following three stages: Stage 1. Within-subject variation in viral load measurements:
where y i ¼ (y i1 (t 1 ), . . . , y im i (t m i )) T are measurements of viral load from the ith subject.
. . , f (y i , t im i )) T are numerical solutions of viral load to the differential equation (3), and e i ¼ (e i (t 1 ), . . . , e i (t m i )) T are mean zero measurement errors.
where m ¼ (log f, log c, log d, log l, log r, log N, log k) T are population parameters and b i are random effects with mean zero.
Stage 3. Hyperprior distributions:
where the mutually independent Gamma (Ga), Normal (N ) and Wishart (Wi) prior distributions are chosen to facilitate computations. The parameters a, b, Z, L, X and n characterize the hyperprior distributions and are assumed to be known.
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It can be shown that the full conditional distributions for the parameters s À2 , l and S À1 may be written explicitly as
whereas the full conditional distribution of each y i , given the remaining parameters and the data, cannot be obtained explicitly. The distribution of [y i js 2 , l, S, Y {i} ,Y] has a density function which is proportional to
Markov chain Monte Carlo (MCMC) methods can be used to obtain the estimates of the posterior distributions of the parameters. In fact, MCMC methods enable one to generate sample from the joint and marginal posterior distributions of unknown quantities in Bayesian models, as well as functions of these unknowns. To implement a MCMC algorithm, Gibbs sampling steps are used to update s À2 , l and S À1 , whereas we update y i , i ¼ 1, . . . , n, using a Metropolis-Hastings step. For the description of the entire MCMC scheme, consisting of a series of Gibbs sampling and Metropolis-Hastings steps, please refer to the literature. [56] [57] [58] [59] It remains to specify the values of the hyperparameters in the prior distributions (14) . These values can be posited from published studies. 1-3,54,60 See Han et al. 54 for the detailed discussion on prior construction. In principle, if we have reliable prior data or information on some of the parameters, we may give a strong prior (smaller variance) for these parameters. For some other parameters, we may not have enough prior information or we may want to use the current clinical data to determine these parameters since they are critical to quantify between-subject variations in the response. In this case, we may use a noninformative prior. We also need to carefully investigate the sensitivity of Bayesian estimates to prior information and initial values of the estimation algorithm. The convergence of MCMC should be monitored carefully. More details can be found in Hung and Wu. 61 In summary, Bayesian methods: 1) provide a useful and efficient way to incorporate prior information into clinical data analysis for identifying more unknown parameters in complex models such as nonlinear differential equation models; 2) allow one to incorporate both point estimates and uncertainties (variances) in the prior into parameter identification; 3) enable the estimate of variances of quantities of interest when asymptotic methods are difficult to apply or inappropriate due to small sample sizes and 4) provide a framework for fitting complex models using MCMC methods.
Practical issues
Except for the semiparametric Model (5), all other viral dynamic models only fit the clinical viral load data during the initial short time period after starting antiviral treatment. One reason is that a closed-form solution is available only when the concentration of target uninfected cells is assumed to be a constant and this is true only during a short time of treatment after the initiation. Another reason is that viral load is likely to rebound during long term treatment owing to the development of drug resistance, poor adherence and other factors. Viral decay models do not fit viral rebound data. Thus, if viral load is off-track of the viral decay trajectory, the data have to be excluded from model fitting. A critical question is how to define a viral rebound. So far there is no standard definition, and thus data truncation is quite arbitrary, which may result in biased estimates. The proposed semiparametric Model (5) may be one way to resolve this problem.
Another practical problem is how to deal with HIV-1RNA data below the limit of quantification (BLQ). The BLQ of HIV-1 RNA assays ranges from 100 to 500 copies per milliliter of plasma for standard assays and 50 copies or lower per milliliter of plasma for ultra-sensitive assays. If the HIV-1 RNA levels fall below the limit of assay quantification during the early stage for a patient, we may impute the BLQ by the quantification limit or half of the limit. But we may only apply the imputation for the first BLQ value for each patient. Note that if more than one BLQ value is imputed and used, it may create an artifical level-off effect. More formal methods for handling BLQ need to be developed.
As viral dynamic models are intrinsically nonlinear in most cases, we have to provide initial values for the model fitting algorithms. In fitting nonlinear models, the linearization method is usually used. In the NLME model fitting, the EM algorithm or the Newton-Raphson method is used to estimate the population parameters and variancecovariance parameters. 43, 44, 48 Thus, how to monitor the convergence of NLS and NLME algorithms is a challenging problem. On the basis of our experience, different initial values may result in a different parameter estimate (sometimes a big difference), that is, the computational algorithms are not stable and are sensitive to initial values. In some cases, one may not even obtain convergence. To avoid this problem, the most common approach is a nonstochatic optimization method (i.e., starting from a large number of chosen initial values) or a grid-search method. The massive search method is computationally intensive. Another problem is that different initial values may lead to different local maxima or minima. It is not trivial to determine which of the maximum or minimum convergence points is the global maxima or minima that we are searching for. The largest maxima or smallest minima is not necessarily the solution because sometimes it may lead to a degenerate model. For NLME model fitting, we found that the population estimates always look reasonable, but the estimates for individual subjects may be largely biased. This may cause problems if we use these individual estimates as derived variables 8 for further analyses. Thus, the diagnostic plots and tools for population and individual estimates need to be used to carefully check the model fitting. Other approaches for dealing with initial values and local maxima/minima include simulated annealing 62, 63 and bootstrap 64 methods. Recently, Wood 64 suggested a bootstrap restarting method that was claimed to be preferable. Small et al. 65 gave a very god survey of multiple root problems.
Perelson et al. 3 have shown that a 'shoulder' effect exists during the first three days of treatment with PI antiviral drugs. This is because the mechanism of PI drugs is to render newly produced virions noninfectious, but they do not inhibit either the production of virions from already infected cells or the infection of new cells by previously produced infectious virions. Owing to the confounding with intracellular and pharmacological delays as observed on the shoulder effect, the clearance of virions cannot be accurately estimated even if the frequent viral load data are available on the shoulder effect. 32 To deal with this problem and to evaluate the effect of the pretreatment steady state assumption, Ding and Wu 66 have conducted extensive simulations to compare the four model fitting strategies. The first is a simple method that just ignores the shoulder effect and fits a biexponential viral dynamic model using all the data from baseline (time 0). The second method, the Wu-Ding method, is the one proposed by Wu and Ding, 33 to fit the biexponential only using the data after the shoulder effect (say, starting from day 2 or 3 of treatment). The third method is the one suggested by Perelson et al., l4 which assumes a pretreatment steady state, and solves the differential equations of viral dynamics (the concentration of uninfected target cells is assumed to be constant) to obtain a closed-form solution. If the frequent viral load data are not available, the clearance rate of virions is assumed to be known from previous studies (the estimate of minimum clearance rate). The fourth method is the same as the third method except that the pretreatment steady state is not assumed. Instead, the macroparameters 33, 66 are introduced into the model.
In summary, the following factors may affect the estimates of viral dynamic parameters: 1) data truncation due to viral rebound or the assay detection limit; 2) different statistical models and estimation methods; 3) different designs of measurement schedules (to be addressed in Section 5); 4) initial values and convergence of estimation algorithms; and 5) different ways of dealing with the 'shoulder' effect. Some comparison studies of different models and estimation methods can be found in Ding and Wu 66 and Wu et al. 67, 68 Careful selection of the estimation models and methods is critical in real clinical data analysis. Also, caution should be taken when one compares the viral dynamic parameters across studies since one needs to make sure that the same estimation model and method are used when comparing their estimate. The convergence of nonlinear regression algorithms needs to be carefully monitored. S-plus functions and SAS procedures are available to fit both nonlinear regression models and mixed-effects models. Computer codes are available from the author upon request.
Statistical inference: treatment comparisons, host factors and predictions
As HIV viral dynamic parameters such as viral decay rates are important markers for the potency of antiviral therapies, [7] [8] [9] 36 investigators are interested in studying the following question: Is there a significant difference in viral dynamic parameters between two treatments? What host factors (baseline covariates) are related to viral dynamic parameters? Are viral dynamic parameters predictive of long term antiviral responses?
In order to answer these questions, statistical inference methods need to be developed. In this section, we survey these methods.
Treatment comparisons
The difference in viral decay rates, estimated from viral dynamic modes, may indicate a difference in the potency of antiviral treatment. [7] [8] [9] 36 As the viral decay rates are estimated quantities, the direct application of hypothesis tests to the estimated values needs to be justified. Ding and Wu 8 suggested three methods. If the viral decay rates are estimated by the NLS method, the derived variable approach 69 may allow us to apply the standard hypothesis tests to the estimated viral decay rates. This method requires that the data are approximately balanced between patients and the individual measurements of HIV RNA copies are frequent enough to fit nonlinear viral dynamic models. Because in practice, not all patients have frequent measurements of viral load and viral load may rebound or fall below the limits of detection, the estimate of viral decay rates from some patients may not be available. In this case, these patients have to be excluded from treatment comparisons and this may lead to bias and inefficiency.
Another method proposed by Ding and Wu 8 is the NLME model based likelihood ratio (LR) test. This method is supposed to be the most powerful in theory, but it requires a large sample and a large number of measurements per subject. In most practical applications with sparse individual data, the LR test may exaggerate the type I error [simulation results are found in Vonesh and Chinchilli 44 (Chapter 7) and Ding and Wu 8 ]. The most favorable method is to apply the derived variable idea to the empirical Bayes estimates (EBE) from the NLME models. Ding and Wu 8 have proposed the following propositions. Proposition 1. The EBEs of viral decay rates from two treatment groups are exchangeable under the null hypothesis that there is no difference in the viral decay rates between the two groups. Proposition 2. IT is valid to apply the wilcoxon rank-sum test, exact Wei-johnson test and O'Brien test to the EBEs of viral decay rates obtained from fitting an NLME model under the null hypothesis that there is no difference in the viral decay rates between the two groups. If in addition, we further assume that the EBEs are normally distributed, then it is valid to apply the parametric two sample t-test or Hotelling T 2 -test to the individual EBEs Simulation studies 8 have shown that the EBE based test is valid and powerful, and thus is suggested for practical use.
Identi¢cation of host factors
It is important to identify what host factors or baseline covariates are predictive of viral decay rates that reflect the potency of antiviral therapies. In most viral dynamic studies, many baseline host factors such as age, gender, race, baseline viral load and CD4þ cell counts are available. We may treat these factors as covariates in the NLME models and use standard covariate selection methods to identify which are significant. 70, 71 However, there are two hurdles that prevent us from using the standard methods: One is the computational difficulty and the other is that the likelihood-based tests require large samples (i.e., the number of measurements for each subject needs to be large), which may not be true in most viral dynamic studies. Wu and Wu 72 suggested that one first conducts univariate analyses to identify individual significant covariates from a large number of baseline factors, and then obtain the optimal subset from these significant covariates using standard covariate selection methods in regression models. Thus, in the following, we will focus on how to identify a single significant covariate.
The standard likelihood-based methods are usually most powerful for studying whether a covariate is significantly related to a response variable. However, for the NLME models, the exact likelihood function cannot be obtained, instead, an approximation is usually used. If the intraindividual data are sparse, and the interindividual variation is large, as is the case in most viral dynamic studies, the approximate likelihood is not reliable. 8, 72 Thus, alternatively derived variable methods have been proposed. 72 One is based on the standard NLS method and another is based on the EBEs from the NLME models. Similar to the treatment comparisons outlined in the last subsection, Wu and Wu 72 have shown that the EBE based method is favorable.
Nonlinear least-squares method
For each individual i, we may fit the nonlinear regression model y i ¼ f(t i , b i ) þ e i , and obtain the individual least square estimatesb i for b i , i ¼ 1, . . ., n. Next, we may conduct a correlation test between (b 1j , . . . ,b nj ) and a baseline covariate (z 1 , . . ., z n ) by standard parametric or nonparametric methods, such as Pearson's correlation test or Spearman's rank correlation test, where (b 1j , . . . ,b nj ) are the n individual LS estimates for the jth component of b (j ¼ 1, . . . , s) . Thus, we can determine whether covariate z is significant for the jth component of b based on the correlation test results. This is called the derived variable approach in Diggle et al. 69 We refer to this method as the NLS method or the NLS-based test in this paper.
Empirical Bayes method
We first fit the nonlinear mixed-effect model, Model (6) and (7), without including any covariate in the second stage (7) . Denote the resulting individual EBE of b i byb i . Then we may conduct a correlation test between (b 1j , . . . ,b nj ) and (z 1 , . . . , z n ) by standard parametric or nonparametric methods, and determine whether the baseline covariate z is significantly correlated with the jth component of b. This methods is called the EB method or the EB-based test.
In the two methods described earlier, the NLS-based test is easily justified based on the arguments of derived variables when the data are balanced and complete, 69 because the individual LS estimates are i.i.d. in this case. In practice, the derived variable approach appears to be used optimistically with moderately incomplete data. For sparse intraindividual data however, an obvious drawback of the NLS-based test is that some individual NLS estimates may not be obtainable because of insufficient data, so we have to discard the data from some subjects. Moreover, for some individuals, even if individual LS estimates can be obtained, the estimates may not be of good quality if they are obtained from the sparse data. If the within-individual measurements are rich enough, the NLS based test may be appealing, but in this case, the standard method such as the most powerful LR test should also work well. 43, 44 The advantage of the EB-based test over the NLS-based test is that the individual EBE are obtained by pooling information across individuals. Thus the EB-based test is favorable when the intraindividual data are sparse, as is the case for large viral dynamic studies. Similar approaches have appeared in Maitre et al. 70 and Mandema et al. 71 without justification.
Another important problem is the missing data problem. It is very common to have missing covariate data in viral dynamic studies. [72] [73] [74] The missing covariate problem in the NLME models has been carefully studied in Wu and Wu. 73, 74 Among the three methods (complete case, mean value imputation and multiple imputation), Wu and Wu 73, 74 have shown that the multiple imputation method 75 is favored. More details on the multiple imputation method for missing covariates in the NLME models can be found in Wu and Wu. [72] [73] [74] 
Prediction of long term responses
As viral decay rates reflect the potency of antiviral regimens, we may want to study whether the potency of a regimen affects long term responses. Intuitively, the potency of a therapy is definitely related to long term responses. However, many other factors, especially long term factors such as compliance, drug resistance and drug exposure may also contribute to the success or failure of an antiviral regimen. Thus, the effect of potency of a regimen on the long term response may not be significant when compared with other factors. Thus, it is necessary to investigate this issue in clinical studies.
The long term response may be measured by the following endpoints: 1) survival endpoints, that is, time to virological success (usually defined as HIV-1 RNA falling below the limit to detection), time to virological failure (viral load rebound) or time to clinical events such as progression to AIDS, adverse events and so on; 2) binary or categorical endpoints, that is, at a given treatment time, say 24 weeks or 48 weeks, whether a subject's RNA level is below the limit of detection, or whether a subject had experienced a particular adverse event and 3) continuous endpoints, that is, viral load change (VLC) from baseline to a given treatment time period, the change in CD4þ cell counts from baseline to a given treatment time period (24 weeks or 48 weeks). Some other endpoints for AIDS clinical trials are summarized in Weinberg and Lagakos. 76 First, viral dynamic parameters such as viral decay rates for each individual are estimated by the NLME models as described in the previous sections. For survival endpoints, the standard proportional hazards model with covariates may be used. The viral decay rates can be treated as covariates. The covariate selection methods or tests can be used to test whether viral decay rates are significantly related to the survival endpoints. For binary or categorical endpoints, a simple method is used to compare the estimated viral decay rates among different categories using two-sample tests or ANOVA for more than two groups. Nonparametric rank tests are usually preferable due to their robustness. A formal analysis may employ the generalized linear models approach. 77 Again, the estimated viral decay rates can be treated as covariates. For continuous endpoints, a simple correlation test (Spearman's rank correlation or Pearson's correlation test) may be used to examine whether the viral decay rates are related to the endpoints. A formal regression analysis may also be used to explore more complicated relationships (including nonlinear relationships). In all these analyses, we treat the estimated viral decay rates as covariates, which is a kind of derived variable approach. 8, 69 One advantage of the derived variable approach is that it is simple and standard methods can be readily applied. However, a formal justification is needed for these analyses.
Design issues
One of the objectives of viral dynamics studies is to assess the potency of antiretroviral therapies. 7, 8, 9, 36 It is critical to design a study which is powerful enough to identify the difference of efficacy between a new treatment regimen and a standard control treatment. The design issues for viral dynamic studies includes: 1) how frequent HIV RNA should be measured and how to allocate the design time points; 2) how to balance the sample size (the number of subjects) and the number of measurements per subject and 3) whether the measurement time points should be the same for all subjects.
Marschner 78 studied the design problems for viral dynamics under a mixed-effects model framework. However, his assumptions are too idealistic and do not reflect methods that can be readily implemented in practice. Wu and Ding 79 used computer simulations to evaluate a finite number of plausible designs of viral dynamic studies. Some practical guidelines are provided. A brief discussion of the design issues of viral dynamic studies was also given by Wu. 80 Computer simulation techniques have been widely used in many areas such as the automobile design and aerospace industries. 81 Recently, these techniques have been introduced into the pharmaceutical industry to optimize the trial design and to maximize the success rate of the actual trials on human subjects, so that the drug development process can be accelerated and the cost reduced. 81 7 and 14) . Notice that, by comparing Schedules 2 and 4, we can evaluate whether the additional samples in the earlier stage (days 1, 3 and 10) can improve the estimates of viral decay rates and the power for treatment comparisons. Similarly, by comparing Schedules 3 and 4, we can evaluate whether the additional samples in the later stage (days 21 and 42) can help. Another reason that these schedules were chosen for evaluation was that they were proposed and currently used in some HIV dynamic studies.
Wu and Ding 79 used intensive Monte Carlo simulations, combined with analytic analyses, to study the different markers and the four different design schedules for assessing the potency of anti-HIV therapies in AIDS clinical trials. We obtained the following important results: 1) the viral decay rate (d 1 ) of the first phase in viral dynamic models is a robust marker for antiviral potency if a frequent measurement schedule of viral load is used, but it is very costly; 2) the phase I viral decay rate d 1 with a sparse (weekly in the first month) measurement schedule is very cost effective, but a large sample size (the number of subjects) is needed; 3) the marker of VLC from baseline is an efficient marker if the optimal measurement time is captured, but the VLC is not robust and 4) in evaluating potent antiviral therapies, the VLC at week 1 or VLC (7) is better than the VLC at later weeks, such as week 2 and week 4, which are currently used in many AIDS clinical trials.
Although it is costly and requires frequent clinical visits which may cause accrual difficulties, marker d 1 with a frequent measurement schedule is still useful. One reason is that it not only provides information regarding the potency of a therapy, but also gives an accurate estimate for viral/cellular dynamics (such as half-life of infected cells [3] [4] [5] [6] ). Secondly, the frequent measurements may help to validate the viral dynamic models used for analysis. However, the intensive viral dynamic study is limited to a very small sample size owing to its high cost and accrual difficulty.
The d 1 marker with a sparse measurement schedule and VLC are effective markers for antiviral potency. We suggest using weekly viral load measurements (or only week 1, 2 and 4) during the first month of treatment. If only one measurement is allowed during the first month of treatment in a large study, we suggest using week 1 or VLC (7) to evaluate the potency of a therapy. A combination of a small substudy for frequent measurements and a large main study with at least a week 1 measurement can be used to gain benefits from both the d 1 and VLC markers. In fact, some clinical data 87 have shown that week 1 VLC is strongly correlated with d 1 , thus may replace d 1 to assess treatment potency, at least in some patient populations in which the relationship has been established.
Discussion, conclusion and future direction
In this article, we have reviewed mathematical models and statistical methods for data analysis of HIV dynamic studies. These models and methods have been used in AIDS clinical trials that have led to important scientific findings in HIV pathogenesis. In particular, we have surveyed the mixed-effects modeling approach for HIV dynamics that includes linear, nonlinear and semiparametric mixed-effects models, as well as the Bayesian approach for parameter estimation. Some practical tips and procedures for statistical inference which are very useful in HIV dynamic data analysis are presented and discussed. The design issues for HIV dynamic studies are addressed. This article provides a systematic review of these useful methods which will be beneficial to Viral dynamic studies 187 biostatisticians, biomathematicians and AIDS researchers who may design and analyse HIV dynamics studies.
It is worthwhile to notice that the models and methodologies presented in this paper are also applicable to dynamic analysis of hepatitis viruses such as HBV and HCV. 88, 89 As the feature of HBV and HCV dynamics is similar to HIV, the statistical methods are similarly applicable to HBV and HCV analyses, although the dynamic models may be different.
Most of the viral dynamic studies focus on short term dynamics and estimating dynamic parameters. However, another important problem is how to study long term dynamics of HIV RNA and T lymphocytes in an AIDS clinical trial. The long term dynamics of HIV RNA and T lymphocytes may provide more information on the long term effectiveness of a treatment and pathogenesis of chronic HIV infection. Nonparametric regression methodologies similar to the semiparametric models that we proposed 35 may play an important role here. Also, how to classify the long term dynamic patterns of virological and immunological markers is a challenging problem. The derived variable approach for statistical inference also needs formal justification for different models. Another interesting area for HIV dynamic modeling is to use state space models for filtering and prediction, as well as dynamic parameter estimation. 90, 91 The viral dynamic models can serve as the state equations, and viral load and/or CD4þ cell counts may serve as the observation variables in the state space model. The Kalman filter can be used to achieve an accurate estimate for all the state variables. 91 Finally, the author would like to point out that HIV dynamic models will be very important in AIDS clinical trial simulations. 31, [81] [82] [83] [84] [85] [86] It will be a very important tool for combining mathematical modeling and statistical inference with computer simulations in AIDS clinical research. We expect that this will be a promising research area for statisticians.
